InfuSystem, a national healthcare service provider specialising in outpatient care, along with its joint venture partner Sanara MedTech have signed a new distribution agreement with ChemoMouthpiece.
SI Healthcare Technologies, previously SI Wound Care, a 50/50 joint venture between Sanara MedTech and InfuSystem, will distribute ChemoMouthpiece’s kits throughout the US.
ChemoMouthpiece offers a device designed to reduce oral mucositis. It received the US Food and Drug Administration (FDA) clearance in February.
The company also closed its private placement round of $10m in upfront capital in the same month.
This device uses cryotherapy to alleviate symptoms in patients receiving stomatotoxic chemotherapy.
This partnership will enhance the availability of ChemoMouthpiece’s products across the nation.
SI Technologies plans to market and distribute these offerings through oncology sales team of InfuSystem, targeting around 3,000 cancer centres.
The joint venture will buy the product kits at a fixed price and pay royalties on net revenues for the use of the product’s intellectual property.
Sanara MedTech has invested $5m for a 6.6% ownership stake in ChemoMouthpiece.
Additionally, SI Technologies holds an option, expiring on 31 January 2029, to purchase the US business of ChemoMouthpiece, including all related US intellectual property.
ChemoMouthpiece president and CEO David Yoskowitz said: “We believe that InfuSystem’s experienced team of seasoned oncology professionals currently calling on approximately 3,000 US cancer centres will accelerate the uptake of the Chemo Mouthpiece, bringing a much-needed option for patients that would otherwise suffer from the debilitating effects of oral mucositis.”
The Chemo Mouthpiece cools the entire oral cavity, causing vasoconstriction that slows and reduces chemotherapy flow in the mouth.
This lowers the risk of developing oral mucositis. Cryotherapy has been studied for decades, and the Chemo Mouthpiece offers improvements over traditional cryotherapy methods.
Sanara MedTech specialises in the North American advanced wound care and surgical tissue repair markets.
Their product lineup includes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft, and FORTIFY FLOWABLE Extracellular Matrix.
In wound care, the company provides BIAKŌS Antimicrobial Skin and Wound Cleanser, BIAKŌS Antimicrobial Wound Gel, and BIAKŌS Antimicrobial Skin and Wound Irrigation Solution.
InfuSystem CEO Richard DiIorio said: “Sanara and InfuSystem entered into our partnership in order to bring together our combined technical, operational and commercial strengths to deliver proprietary efficacious products to patients.”
